As previously reported, the Patented Medicine Prices Review Board (PMPRB) extended the consultation period for its draft Guidelines to February 14, 2020. Submissions from the consultation are now available to the public on the PMPRB’s website.
In addition, the hearing of the Federal Court challenge to the amended Patented Medicines Regulations (reported here), has been adjourned to June 1 and 2, 2020. BIOTECanada, the Intellectual Property Owners Association, and the Canadian Organization for Rare Disorders have moved for intervener status in the proceeding.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.